Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer.

Decker T, Marschner N, Muendlein A, Welt A, Hagen V, Rauh J, Schröder H, Jaehnig P, Potthoff K, Lerchenmüller C.

Breast Cancer Res Treat. 2019 Aug;176(3):637-647. doi: 10.1007/s10549-019-05280-2. Epub 2019 May 21.

PMID:
31115844
2.

Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIR.

Fietz T, Lück A, Schulz H, Harde J, Losem C, Grebhardt S, Wolff T, Potthoff K, Müller U, Zaiss M, Kurbacher CM.

Curr Med Res Opin. 2019 Jul;35(7):1127-1138. doi: 10.1080/03007995.2018.1560200. Epub 2019 Jan 21.

PMID:
30557099
3.

Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with non-Hodgkin lymphoma (NADIR study).

Wolff T, Schulz H, Losem C, Reichert D, Hurtz HJ, Sandner R, Harde J, Grebhardt S, Potthoff K, Mueller U, Fietz T.

Eur J Haematol. 2019 Feb;102(2):174-181. doi: 10.1111/ejh.13189. Epub 2018 Nov 23.

PMID:
30347466
4.

Targeting Exercise Interventions to Patients With Cancer in Need: An Individual Patient Data Meta-Analysis.

Buffart LM, Sweegers MG, May AM, Chinapaw MJ, van Vulpen JK, Newton RU, Galvão DA, Aaronson NK, Stuiver MM, Jacobsen PB, Verdonck-de Leeuw IM, Steindorf K, Irwin ML, Hayes S, Griffith KA, Lucia A, Herrero-Roman F, Mesters I, van Weert E, Knoop H, Goedendorp MM, Mutrie N, Daley AJ, McConnachie A, Bohus M, Thorsen L, Schulz KH, Short CE, James EL, Plotnikoff RC, Arbane G, Schmidt ME, Potthoff K, van Beurden M, Oldenburg HS, Sonke GS, van Harten WH, Garrod R, Schmitz KH, Winters-Stone KM, Velthuis MJ, Taaffe DR, van Mechelen W, José Kersten M, Nollet F, Wenzel J, Wiskemann J, Brug J, Courneya KS.

J Natl Cancer Inst. 2018 Nov 1;110(11):1190-1200. doi: 10.1093/jnci/djy161.

5.

Effects and moderators of exercise on muscle strength, muscle function and aerobic fitness in patients with cancer: a meta-analysis of individual patient data.

Sweegers MG, Altenburg TM, Brug J, May AM, van Vulpen JK, Aaronson NK, Arbane G, Bohus M, Courneya KS, Daley AJ, Galvao DA, Garrod R, Griffith KA, Van Harten WH, Hayes SC, Herrero-Román F, Kersten MJ, Lucia A, McConnachie A, van Mechelen W, Mutrie N, Newton RU, Nollet F, Potthoff K, Schmidt ME, Schmitz KH, Schulz KH, Sonke G, Steindorf K, Stuiver MM, Taaffe DR, Thorsen L, Twisk JW, Velthuis MJ, Wenzel J, Winters-Stone KM, Wiskemann J, Chin A Paw MJ, Buffart LM.

Br J Sports Med. 2019 Jul;53(13):812. doi: 10.1136/bjsports-2018-099191. Epub 2018 Sep 4.

PMID:
30181323
6.

Final Effectiveness and Safety Results of NABUCCO: Real-World Data From a Noninterventional, Prospective, Multicenter Study in 697 Patients With Metastatic Breast Cancer Treated With nab-Paclitaxel.

Marschner N, Salat C, Söling U, Hansen R, Grebhardt S, Harde J, Nusch A, Potthoff K.

Clin Breast Cancer. 2018 Dec;18(6):e1323-e1337. doi: 10.1016/j.clbc.2018.07.010. Epub 2018 Aug 10.

7.

Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study).

Wehmeyer J, Zaiss M, Losem C, Schmitz S, Niemeier B, Harde J, Hannig CV, Harich HD, Müller J, Klausmann M, Tessen HW, Potthoff K.

Eur J Haematol. 2018 Dec;101(6):766-773. doi: 10.1111/ejh.13160. Epub 2018 Oct 25.

PMID:
30091166
8.

Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials.

Knauf W, Aldaoud A, Losem C, Mittermueller J, Neise M, Niemeier B, Harde J, Trarbach T, Potthoff K.

Leuk Res. 2018 May;68:90-97. doi: 10.1016/j.leukres.2018.03.008. Epub 2018 Mar 14.

PMID:
29579627
9.

20th century Betula pubescens subsp. czerepanovii tree- and forest lines in Norway.

Bryn A, Potthoff K.

Biodivers Data J. 2017 Nov 23;(5):e22093. doi: 10.3897/BDJ.5.e22093. eCollection 2017.

10.

Determinants of physical, affective, and cognitive fatigue during breast cancer therapy and 12 months follow-up.

Schmidt ME, Wiskemann J, Schneeweiss A, Potthoff K, Ulrich CM, Steindorf K.

Int J Cancer. 2018 Mar 15;142(6):1148-1157. doi: 10.1002/ijc.31138. Epub 2017 Nov 13.

11.

Effects and moderators of exercise on quality of life and physical function in patients with cancer: An individual patient data meta-analysis of 34 RCTs.

Buffart LM, Kalter J, Sweegers MG, Courneya KS, Newton RU, Aaronson NK, Jacobsen PB, May AM, Galvão DA, Chinapaw MJ, Steindorf K, Irwin ML, Stuiver MM, Hayes S, Griffith KA, Lucia A, Mesters I, van Weert E, Knoop H, Goedendorp MM, Mutrie N, Daley AJ, McConnachie A, Bohus M, Thorsen L, Schulz KH, Short CE, James EL, Plotnikoff RC, Arbane G, Schmidt ME, Potthoff K, van Beurden M, Oldenburg HS, Sonke GS, van Harten WH, Garrod R, Schmitz KH, Winters-Stone KM, Velthuis MJ, Taaffe DR, van Mechelen W, Kersten MJ, Nollet F, Wenzel J, Wiskemann J, Verdonck-de Leeuw IM, Brug J.

Cancer Treat Rev. 2017 Jan;52:91-104. doi: 10.1016/j.ctrv.2016.11.010. Epub 2016 Dec 5. Review.

12.

Muscle strength in breast cancer patients receiving different treatment regimes.

Klassen O, Schmidt ME, Ulrich CM, Schneeweiss A, Potthoff K, Steindorf K, Wiskemann J.

J Cachexia Sarcopenia Muscle. 2017 Apr;8(2):305-316. doi: 10.1002/jcsm.12165. Epub 2016 Nov 28.

13.

Effects of 12-week resistance training during radiotherapy in breast cancer patients.

Wiskemann J, Schmidt ME, Klassen O, Debus J, Ulrich CM, Potthoff K, Steindorf K.

Scand J Med Sci Sports. 2017 Nov;27(11):1500-1510. doi: 10.1111/sms.12777. Epub 2016 Oct 5.

PMID:
27704628
14.

Resistance Exercise and Inflammation in Breast Cancer Patients Undergoing Adjuvant Radiation Therapy: Mediation Analysis From a Randomized, Controlled Intervention Trial.

Schmidt ME, Meynköhn A, Habermann N, Wiskemann J, Oelmann J, Hof H, Wessels S, Klassen O, Debus J, Potthoff K, Steindorf K, Ulrich CM.

Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):329-37. doi: 10.1016/j.ijrobp.2015.10.058. Epub 2015 Nov 2.

PMID:
26853341
15.

Factors influencing participation in a randomized controlled resistance exercise intervention study in breast cancer patients during radiotherapy.

Gollhofer SM, Wiskemann J, Schmidt ME, Klassen O, Ulrich CM, Oelmann J, Hof H, Potthoff K, Steindorf K.

BMC Cancer. 2015 Mar 27;15:186. doi: 10.1186/s12885-015-1213-1.

16.

Randomized, controlled trial of resistance training in breast cancer patients receiving adjuvant radiotherapy: results on cancer-related fatigue and quality of life.

Steindorf K, Schmidt ME, Klassen O, Ulrich CM, Oelmann J, Habermann N, Beckhove P, Owen R, Debus J, Wiskemann J, Potthoff K.

Ann Oncol. 2014 Nov;25(11):2237-43. doi: 10.1093/annonc/mdu374. Epub 2014 Aug 5.

17.

Cardiorespiratory fitness in breast cancer patients undergoing adjuvant therapy.

Klassen O, Schmidt ME, Scharhag-Rosenberger F, Sorkin M, Ulrich CM, Schneeweiss A, Potthoff K, Steindorf K, Wiskemann J.

Acta Oncol. 2014 Oct;53(10):1356-65. doi: 10.3109/0284186X.2014.899435. Epub 2014 May 16.

PMID:
24837860
18.
19.
21.

Posterior reversible leukoencephalopathy syndrome associated with pazopanib.

Foerster R, Welzel T, Debus J, Gruellich C, Jaeger D, Potthoff K.

Case Rep Oncol. 2013 Apr 6;6(1):204-8. doi: 10.1159/000350742. Print 2013 Jan.

22.

Randomized controlled trial to evaluate the effects of progressive resistance training compared to progressive muscle relaxation in breast cancer patients undergoing adjuvant radiotherapy: the BEST study.

Potthoff K, Schmidt ME, Wiskemann J, Hof H, Klassen O, Habermann N, Beckhove P, Debus J, Ulrich CM, Steindorf K.

BMC Cancer. 2013 Mar 28;13:162. doi: 10.1186/1471-2407-13-162.

23.

Remission of refractory Crohn's disease by high-dose cyclophosphamide and autologous peripheral blood stem cell transplantation.

Hasselblatt P, Drognitz K, Potthoff K, Bertz H, Kruis W, Schmidt C, Stallmach A, Schmitt-Graeff A, Finke J, Kreisel W.

Aliment Pharmacol Ther. 2012 Oct;36(8):725-35. doi: 10.1111/apt.12032. Epub 2012 Sep 2.

24.

Radiochemoimmunotherapy with intensity-modulated concomitant boost: interim analysis of the REACH trial.

Jensen AD, Krauss J, Potthoff K, Simon C, Nikoghosyan AV, Lossner K, Debus J, Münter MW.

Radiat Oncol. 2012 Apr 2;7:57. doi: 10.1186/1748-717X-7-57.

25.

Endoscopic diagnosis of acute intestinal GVHD following allogeneic hematopoietic SCT: a retrospective analysis in 175 patients.

Kreisel W, Dahlberg M, Bertz H, Harder J, Potthoff K, Deibert P, Schmitt-Graeff A, Finke J.

Bone Marrow Transplant. 2012 Mar;47(3):430-8. doi: 10.1038/bmt.2011.137. Epub 2011 Jun 27.

26.
27.

Treatment of locally advanced carcinomas of head and neck with intensity-modulated radiation therapy (IMRT) in combination with cetuximab and chemotherapy: the REACH protocol.

Habl G, Jensen AD, Potthoff K, Uhl M, Hof H, Hajda J, Simon C, Debus J, Krempien R, Münter MW.

BMC Cancer. 2010 Nov 26;10:651. doi: 10.1186/1471-2407-10-651.

28.

Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion.

Potthoff K, Hofheinz R, Hassel JC, Volkenandt M, Lordick F, Hartmann JT, Karthaus M, Riess H, Lipp HP, Hauschild A, Trarbach T, Wollenberg A.

Ann Oncol. 2011 Mar;22(3):524-35. doi: 10.1093/annonc/mdq387. Epub 2010 Aug 13.

29.

Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies.

Marks R, Potthoff K, Hahn J, Ihorst G, Bertz H, Spyridonidis A, Holler E, Finke JM.

Blood. 2008 Jul 15;112(2):415-25. doi: 10.1182/blood-2007-08-104745. Epub 2008 May 1.

PMID:
18451310
30.
31.

Fatal leukoencephalopathy after reduced-intensity allogeneic stem cell transplantation.

Mielke S, Potthoff K, Feuerhake F, Bley TA, Windfuhr M, Bertz H, Finke J.

Onkologie. 2007 Feb;30(1-2):49-52. Epub 2007 Jan 26.

PMID:
17264526
32.

Complete remission of Crohn's disease after high-dose cyclophosphamide and autologous stem cell transplantation.

Kreisel W, Potthoff K, Bertz H, Schmitt-Graeff A, Ruf G, Rasenack J, Finke J.

Bone Marrow Transplant. 2003 Aug;32(3):337-40.

PMID:
12858208
33.
35.

Nosocomial diarrhea caused by Salmonella derby infection in two patients on chemotherapy.

Philippczik G, Fehrenbach J, Steinbrückner B, Potthoff K, Spyridonidis A, Lindemann A, Kist M, Bauer TM.

Clin Microbiol Infect. 1999 Sep;5(9):586-588. No abstract available.

36.
37.
38.

TNF activates NF-kappa B by phosphatidylcholine-specific phospholipase C-induced "acidic" sphingomyelin breakdown.

Schütze S, Potthoff K, Machleidt T, Berkovic D, Wiegmann K, Krönke M.

Cell. 1992 Nov 27;71(5):765-76.

PMID:
1330325
39.

Supplemental Content

Loading ...
Support Center